Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) has evolved into a major pandemic called coronavirus disease 2019 (COVID-19) that has created unprecedented global health emergencies and emerged as a serious threat due to its strong ability for human-to-human transmission. The reports indicate the ability of SARS-CoV-2 to affect almost any organ due to the presence of a receptor known as angiotensin converting enzyme 2 (ACE2) across the body. ACE2 receptor is majorly expressed in brush border of gut enterocytes along with the ciliated cells and alveolar epithelial type II cells in lungs. The amino acid transport function of ACE2 has been linked to gut microbial ecology in gastrointestinal (GI) tract, thereby suggesting that COVID-19 may, to some level, be linked to the enteric microbiota. The significant number of COVID-19 patients shows extra-pulmonary symptoms in the GI tract. Many subsequent studies revealed viral RNA of SARS-CoV-2 in fecal samples of COVID-19 patients. This presents a new challenge in the diagnosis and control of COVID-19 infection with a caution for proper sanitation and hygiene. Here, we aim to discuss the immunological co-ordination between gut and lungs that facilitates SARS-CoV-2 to infect and multiply in the inflammatory bowel disease (IBD) and non-IBD patients.

严重急性呼吸综合征冠状病毒 2 (SARS-CoV-2) 已演变成一种名为 2019 年冠状病毒病 (COVID-19) 的重大流行病，造成了前所未有的全球卫生紧急情况，并因其强大的人类传播能力而成为严重威胁。 -人类传播。报告表明，由于体内存在一种称为血管紧张素转换酶 2 (ACE2) 的受体，SARS-CoV-2 能够影响几乎所有器官。 ACE2受体主要表达于肠道肠上皮细胞的刷状缘以及肺中的纤毛细胞和肺泡上皮II型细胞。 ACE2 的氨基酸转运功能与胃肠道 (GI) 的肠道微生物生态有关，因此表明 COVID-19 在某种程度上可能与肠道微生物群有关。大量 COVID-19 患者在胃肠道中表现出肺外症状。随后的许多研究揭示了 COVID-19 患者粪便样本中的 SARS-CoV-2 病毒 RNA。这对诊断和控制 COVID-19 感染提出了新的挑战，同时要注意适当的环境卫生和个人卫生。在这里，我们的目的是讨论肠道和肺部之间的免疫协调，促进 SARS-CoV-2 在炎症性肠病 (IBD) 和非 IBD 患者中感染和繁殖。